Top

Published in:

01-12-2007 | Correspondence

Atypical Antipsychotic-Induced Diabetes Mellitus in Child and Adolescent Psychiatry

Authors: Dan Cohen, Saskia Huinink

Published in: CNS Drugs | Issue 12/2007

Excerpt

In their valuable article on children with schizophrenia published recently in CNS Drugs, Masi et al.[1] discuss the literature on the pharmacological treatment of this severely debilitating disorder. The authors rightly observe that disturbance of glucose homeostasis is one of the unwanted side effects of treatment with atypical antipsychotic drugs. We would like to contribute further to the understanding of this problem. …

Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs 2006; 20(10): 841–66PubMedCrossRef

Sporn AL, Bobb AJ, Gogtay N, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 2005; 44(9): 925–33PubMedCrossRef

Quintana H, Wilson II MS, Purnell W, et al. An open-label study of olanzapine in children and adolescents with schizophrenia. J Psychiatr Pract 2007; 13(2): 86–96PubMedCrossRef

Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia. Arch Gen Psychiatry 2006; 63: 721–30PubMedCrossRef

Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, et al. Safety and usage of atypical antipsychotic medicines in children. Drug Safety 2007; 30(7): 569–79PubMedCrossRef

Fleischhaker C, Heiser P, Hennghausen K, et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm 2007; 11: 273–80CrossRef

Jensen PS, Buitelaar J, Pandina GJ, et al. Management of psychoiatric disorders in children and adolescents with atypical antipsychotics. Eur Child Adolesc Psychiatry 2007; 16(2): 104–20PubMedCrossRef

Patel NC, Crismon ML, Hoagwood K, et al. Trends in use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44(6): 548–56PubMedCrossRef

Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with anti-psychotic drugs. Arch Gen Psychiatry 2006; 63: 679–85PubMedCrossRef

10.

Bloch Y, Vardi O, Mendlovic S, et al. Hyperglycemia from olanzapine treatment in adolescents. J Child Adolesc Psychopharmacol 2003; 13(1): 97–102PubMedCrossRef

11.

Courvoisie HE, Cooke DW, Riddle MA. Olanzapine-induced diabetes in a seven-year-old boy. J Child Adolesc Psychopharmacol 2004; 14(4): 612–6PubMedCrossRef

12.

Domon SE, Webber JC. Hyperglycemia and hypertriglyceridemia secondary to olanzapine [letter]. J Child Adolesc Psychopharmacol 2001; 11(3): 285–8PubMedCrossRef

13.

Hayek D, Hüttl V, Reiss J, et al. Hyperglycemia and ketoacidosis with olanzapine [in German]. Nervenarzt 1999; 70: 836–7CrossRef

14.

Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatry 2002; 41(5): 495–6PubMedCrossRef

15.

Saito E, Kafantaris V. Can diabetes mellitus be induced by medication? J Child Adolesc Psychopharmacol 2002; 12(3): 231–6PubMedCrossRef

16.

Lauwers K, De Hert M. Glucose abnormalities in a non-psychotic patient treated with risperidone [letter]. J Am Acad Child Adolesc Psychiatry 2005; 44(7): 629–30PubMedCrossRef

17.

Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatrics 2001; 138(6): 936–7CrossRef

18.

Paizis M, Cavaleri S, Schwarz ME, et al. Acute-onset diabetic keotacidosis during olanzapine treatment in a patient without pretreatment obesity or treatment-associated weight gain. Prim Psychiatry 1999; 6(12): 37–8

19.

Koller E, Malozowski S, Doraiswamy PM. Atypical anti-psychotic drugs and hyperglycemia in adolescents [letter]. JAMA 2001; 286: 2547–8PubMedCrossRef

20.

Koller EA, Cross JT, Schneider B. Risperidone-associated diabetes mellitus in children [letter]. Pediatrics 2004; 113: 421–2PubMedCrossRef

21.

Hagura R, Matsuda A, Kuzuya T, et al. Family history of diabetic patients in Japan. Diabetes Res Clin Practice 1994; 24 Suppl: 69–73SCrossRef

22.

Blokstra A, Smit HA, Verschuren WMM. Changes in lifestyle factors and risk factors for chronic diseases with ageing: The Doetinchem Study 1987–2002. Bilthoven: National Institute for Public Health and the Environment, 2006. Report no. 260401003

23.

Cohen D. Atypical antipsychotics and new onset diabetes mellitus: an overview of the literature. Pharmacopsychiatry 2004; 37: 1–11PubMed

24.

Basu A, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophrenia Res 2006; 86: 99–109CrossRef

25.

Ramaswamy K, Kozma CM, Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperdone or olanzapine. Drugs Safety 2007; 30(7): 589–99CrossRef

26.

‘Schizophrenia and Diabetes 2003’. Expert consensus meeting, Dublin, 3–4 October 2003: consensus summary. Br J Psychiatry 2004; 184 (47 Suppl.): 112-4S

27.

Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334–9PubMedCrossRef

28.

Melkersson KI, Dahl M-L, Hulting AL. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacol 2004; 175: 1–6

29.

Gough S, Peveler R. Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br J Psychiatry 2004; 184(47 Suppl.): 106–1SCrossRef

30.

Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 492–501PubMed

31.

Cohen D. Diabetes mellitus in schizophrenia or schizoaffective disorder: an iatrogenic or endogenic problem? [dissertation]. Haarlem: University of Utrecht, 2006: 91–103

Title: Atypical Antipsychotic-Induced Diabetes Mellitus in Child and Adolescent Psychiatry
Authors: Dan Cohen
Saskia Huinink
Publication date: 01-12-2007
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 12/2007
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200721120-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Atypical Antipsychotic-Induced Diabetes Mellitus in Child and Adolescent Psychiatry

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2007

Recommendations for the Use of Pharmacological Smoking Cessation Strategies in Pregnant Women

Cognitive Dysfunction in Bipolar Disorder

Role of the Melatonin System in the Control of Sleep

Rotigotine Transdermal Patch

Acknowledgement

Valproate Use in Children and Adolescents with Bipolar Disorder